Peri-procedural antithrombotic bridging and the assessment of the associated risk of major bleeding

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 9-10

  Limantoro, Ione ^a   Pisters, Ron ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

AGE; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING; CATHETER ABLATION; DISEASE PREDISPOSITION; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER FUNCTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

ANTICOAGULANTS; FEMALE; HEART CATHETERIZATION; HEART DISEASES; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; PROSTHESIS IMPLANTATION;

EID: 84863678918     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-05-0333     Document Type: Article

References (15)

1. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
2. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
4. Omran H, Bauersachs R, Rubenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation: Results from the national multicenter BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
5. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 2008; 6: 1615-1621.
6. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association (1), endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
7. Jamula E, Lloyd NS, Schwalm JD, et al. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis. Chest 2010; 138: 840-847.
8. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28.
9. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-571.
10. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
11. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
12. Winkle RA, Mead RH, Engel G, et al. The Use of Dabigatran Immediately After Atrial Fibrillation Ablation. J Cardiovasc Electrophysiol 2012; 23: 264-268.
13. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
14. Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. Circulation Arrhyth Electrophysiol 2012; 5: 312-318.
15. Roldan V, Marin F, Manzano-Fernandez S, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. Chest 2012; in press.